Curing HCV infection with direct-acting antiretrovirals is associated with regression of liver fibrosis for most patients.
The researchers found a significant difference in mean time to direct-acting antiviral agent treatment among participants with public insurance payers compared with private insurance payers.
The neuropsychiatric symptoms associated with HCV infection are likely caused by the body's response to the virus' effects on brain function.
Direct-acting antivirals are safe and effective in African-American patients with chronic HCV.
There is an opportunity to improve HCV treatment rates for people who inject drugs by integrating DAA therapy into current models of community-based addiction.
All 20 recipients experienced HCV cure, good quality of life, excellent renal function.
Investigators added hepatitis C virus and HIV screening tests to standard trauma activation laboratory orders.
Coordinated treatment programs may improve treatment outcomes in patients with hepatitis C infection.
Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.
Successful DAA therapy may lead to cognitive improvement in several domains in HCV-infected patients.
Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women
The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.
A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.
Patients with mild, moderate renal impairment showed improvement in renal biomarkers over one year
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
In this retrospective study, only a fraction of infants receiving well-child care at the study institution were screened for hepatitis C, despite being born to mothers with a known history of hepatitis C virus infection.
Screening prevalence 11.5 to 12.8%; similar rate for cohort born from 1966 to 1985
In this large, real-world cohort of patients with chronic hepatitis C virus infection, equivalent sustained virologic response rates were found with both 8-week and 12-week treatment.
Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.
Prophylaxis safely, effectively prevents HCV transmittance in noninfected patients receiving kidney transplants from HCV-positive donors.
Elbasvir and grazoprevir, taken in combination for 12 weeks, successfully treated virologic response in patient with hepatitis C genotype 1b.
Once daily glecaprevir-pibrentasvir for 8 or 12 weeks successfully treated HCV genotype 1 and 3.
Patients with chronic HCV with a sustained virologic response were more likely to have a reduced progression of liver fibrosis.
Hepatitis B and hepatitis C may increase mortality risks in HIV patients.
Hepatitis C treatment improves outcomes and experiences for patient and provider.
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America have added updates to the hepatitis C guidelines to include kidney transplant, pregnant, and pediatric patients.
The results show no evidence to support a hypothesis of differential impact of interferon and direct-acting antiviral-based cure on risk for HCC occurrence and recurrence.
Primary care providers and nurse practitioners achieve the same sustained virologic response rates as specialists.
The prompt increased hepatitis C screening rates among baby boomers in primary care by 5-fold.